Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2014

View Archived Issues

Nihon Medi-Physics and Endocyte sign license agreement for companion diagnostic

Moderna launches new venture to focus on development of mRNA Therapeutics in oncology

Elixir Medical confirms first commercial implant of the DESolve scaffold system

Sanofi and Fraunhofer-Gesellschaft form natural product center of excellence for infectious diseases

Mass General, Broad Institute and Amgen form collaboration to treat IBD

IntegraGen enters collaboration to validate oncology biomarker

Resverlogix reports results from analysis of combined data from SUSTAIN and ASSURE trials

Patch under development by Taisho and Tokuhon shows efficacy in phase III trials in osteoarthritis

Tafinlar receives FDA breakthrough therapy designation for NSCLC with BRAF mutation

TS-734 shows promise as PET-imaging agent for early detection and treatment of Alzheimer's disease

Nab-paclitaxel shows promise in esophageal squamous cell carcinoma trial

Identification of a risk factor inversely correlated with cardiometabolic disease

Cytonet files MAA with EMA for use of liver cell therapy to treat urea cycle disorders in children

Japan Tobacco and Torii gain approval for Riona Tablets in Japan

Suglat tablets approved for treatment of type 2 diabetes in Japan

Xyzal syrup for allergic disease gains approval in Japan

SYK inhibitors revealed in Portola patents

Status updates provided for phase III METIV-HCC and ATTENTION trials of tivantinib

Metabotropic glutamate mGlu5 receptor PAMs reported in Vanderbilt University patent

Takeda obtains approval of Adcetris for treatment of malignant lymphoma in Japan

Merck & Co. researchers report discovery of SYK inhibitors

Torii's sublingual immunotherapy drug for Japanese cedar pollinosis approved in Japan

Japanese MHLW approves Bayer's Adempas for CTEPH

FDA committee votes against approval of rivaroxaban for ACS indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...